Glaukos Corp Stock
Glaukos Corp Stock
The price for the Glaukos Corp stock decreased slightly today. Compared to yesterday there is a change of -€1.000 (-0.690%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Glaukos Corp stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Glaukos Corp in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Glaukos Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Glaukos Corp | -0.690% | 5.882% | 11.628% | 95.918% | 49.223% | 114.925% | 249.515% |
| Haemonetics Corp. | 1.340% | 7.092% | 14.394% | - | 10.219% | - | - |
| Bio-Rad Labs Inc. A | 3.260% | 4.601% | 11.494% | 18.149% | 12.834% | -20.881% | -53.810% |
| Penumbra Inc | -0.140% | -0.783% | 0.578% | 33.942% | 4.580% | 19.060% | 26.063% |
News
Glaukos Q2 Earnings Call Highlights
Key Points
- Interested in Glaukos Corporation? Here are five stocks we like better.
- Record Q2 sales: Glaukos reported $185.6 million in second-quarter revenue, up 50% year over year, driven by
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Alex R. Thurman, SVP & Chief Financial Officer of Glaukos Corporation (NYSE:GKOS), sold 10,000 shares of common stock on July 9, 2026, according to an SEC Form 4 filing.
Transaction value based on
